commercial first share I'm quarter results. you, our excited Thank to Barry.
We ZYNRELEF continue the significant launch. to progress make with
date by my I'll quarter start During care progress. start an this of highlights indicators. And on sharing first results then oncology a strong metrics ZYNRELEF with by to to update finish launch scorecard business. updates the leading on presentation, our number related our summarizing key I'll I'll with of with our commercial performance
grown account of also growing been nine month. launch from three During a by per adding first the the continued the months to about months accounts, accounts launch, our in rates, first launch. the quarters new reorder which encouraged which unique three of XX% cadence we of We're in ordering have strong in increases by XX% XX of first have very have
hospitals ZYNRELEF launch. with for to rate and XX approvals targeted gain formulary a approvals formulary of run our per month continue We during
the IDN ZYNRELEF formulary. interchanges support or potential critical future. believe accounts to with procedures from adding adding IDNs in We to Importantly, excellent switching therapeutic key in component growth Exparel we're networks seeing a integrated is delivery ZYNRELEF for in indicated
since since an which call, ZYNRELEF of a the unique of separate in ordering surgical competitive last Slide for This Symphony separately based Finally, the reimbursement advantage local reimbursed status has is number our is Health procedures. earnings bundle key XX% for outpatient of payment. estimated outside received the launch hospital the ZYNRELEF pass-through ZYNRELEF only X nine benchmarks represents of our indicated the data. on accounts setting first of care, number during months anesthetic
from ordering We of continue nine to launch. rapidly in the This with of accounts level first represents the XXX of increase launch. first in months six add XX% ZYNRELEF new the accounts XXX an months ordering
greatest analysis. had surgeons products patients. is addition, XX% their of for four believe reorder excellent world reordering in ZYNRELEF an are In having growing accounts all of the that real the rate indication this the nine We benchmarked percentage experience with months, first strong the during reorder
While strong next ZYNRELEF slide. we XXXX. are expansion April, initial number is X,XXX ordering bringing the my In the to show goal in first first in we results total XX on to fourth This added make the progress of in unit of strong, a continued from our priority I'll during April, accounts accounts, orders ordering unique total ZYNRELEF accounts. the as in XX% quarter over the grew new aggressive demand And key XX in XXX target XX% ZYNRELEF of months account launch. our quarter. represents by this
Omicron half February. that stunted However, of the during it's surge second ZYNRELEF recognize December important into to early the COVID
a customers pre-op were growth we were monthly surgeries elective March. for of to able our and XX% for result February shortages. faced positive test with COVID surge, as Nevertheless, XX% to delays demonstrate decisions, in policy staff and the patient During
based of bariatric foot strength dosage on the first this indication, procedures, label demand quarter, units utilized which surgical such During XXX-milligram as expansion for over and SKU ankle. the ZYNRELEF’s by grew broad XXX%,
April in total slowed demand launch, the months While the two in quarter. compared the April growth monthly since was first highest months to prior the
of based prior at surgeons. five-week that and the five-week slowdown a procedures for spring test our March of elective with period to first this ending feedback, looked and the we late During XXth In period. break team April, patients rolling compared sales the weeks of couple on reported and order April
in The ZYNRELEF continues slide demand of level this during X% actually to this As time of be the period, by ZYNRELEF Exparel XX% while area great an distribution shows, channel the period. same interest. declined inventory by during grew
As fourth initial distribution volume was call, time, stocking quarter Since in increases meaningful unit excess progress based continued in that there in the make burning to that we've we channel. on ZYNRELEF our inventory demand inventory described sales. in through
unit the in of to In better progress the inventory First orders channel reporting was both $X.X channel, demand our we demand are at draw based was XXX% continued XXX-milligram on quarter rate understand SKU $XXX,XXX which XX% and every stocking based net and demand sales replenishing XXst, ex-factory inventory sold, inventory the for product volume, SKUs. of for short-dated million, volume. unit the demand or order and rates were to initial down the ASCs. reorder distribution unit orders reorder have on the net goal ex-factory volume meaning hospital ASC. March their is hospitals demand from returns for unit distribution Ultimately, is level Through to of
May XX%, respect XXX-milligram of unit channel stabilized This Fortunately words, first the XXX-milligram with some ex-factory distribution unit. through sales surprising the through excess In -- should XXX% XXX-milligram With the be a in the volume. go ex-factory March reorder of Xrd in the March SKU Xrd the XX% with isn't reflected there indicating XXX-milligram exceeds We've at for SKU, units through ZYNRELEF SKU or inventory the end quarter. May other the rate of improvement ZYNRELEF to reorder the was we as demand right growth XXX-milligram rate, demand already based forward. ex-factory and has observed the accelerating of now SKU. XXst ex-factory order the was total reorder significant the Xrd, XX% on demand unit rate XXX-milligram accounting in
remaining in We inventory of expect the the the like the second first the XXX-milligram by did excess just to quarter. end burn SKU through we with quarter, XXX-milligram
to P&T of into new to is dive month at And we total making decisions, are end February, approvals. since business pipeline. grow approvals. the continued At of ZYNRELEF to number launch the committees actually continued formulary reported new formulary. slide accounts Now, approvals P&T This about XX% XXX let's over the This highlights approvals. XX rapid of hospital per adding ZYNRELEF XXX has that those our details formulary with formulary progress making the
for gaining remainder by end about the expansion -- estimated an formulary of usage ZYNRELEF to P&T of formulary label of excellent additional to XX review second expanding will the XX% of our The the contain are ZYNRELEF. quarter approved include approvals unrestricted the approval committees in broader We're Importantly, mid-December. the of in quarter. before unrestricted also progress scheduled making the FDA
third the approval a addition, reviews new a one and available products for committee in P&T number moratorium which IDNs, of year all add to FDA implement In become will following hospitals quarter.
remain help approvals for critical establish business pipeline a a priority new formulary our team. ZYNRELEF commercial New key for us and
highlight of Next, X,XXX targeting system their approvals I IDN new in system-wide formularies. ZYNRELEF Exparel delivery IDNs added include procedures. networks to to wanted ZYNRELEF. interchange opportunities far, use ZYNRELEF have a institutions from unrestricted therapeutic to IDNs integrated These the of top indicated strategy with for key or Thus to down XX systems for for over create XX% their of
about XX these XX XXX,XXX Exparel indicated sales. million account procedures of addition, for annual IDNs In ZYNRELEF and
work with to Exparel success from level switching procedures. to with decision ZYNRELEF indicated Our evaluating IDN who’re us senior makers allows for
not therapeutic superior IDNs in actually bupivacaine. ZYNRELEF’s XX interchange. the clinical save potential label interested expanded demonstrated is it's to of the are which of on down standard surprising product, that drill for a IDNs let's dollars Now, that to looking are results millions care, indications, With a
their trials trials with XX very ZYNRELEF. initiated variety be partnering surgical their the of procedures. drive XX already thrilled ZYNRELEF. across has feedback are Initial with are to both, We evaluations we pharmacy physicians internal Of been internal on have positive and to the with wide interested, a IDNs
the IDN reimbursement now a are ago. years actually outpatient we of important bupivacaine, builds patients Medicare three existing for made of setting beyond the decision the the already reimbursed quarter. significant reimbursement moving effective is since for interchange therapeutic advantage CMS the period. this generic separate care, our on in a care pass-through CXXXX is only ZYNRELEF the While outpatient next The approval XXXX issued for ZYNRELEF the status game-changer to time, separately CMS hospital using anesthetics large quarter, place. expired status some permanent for is the for in and be reimbursement reimbursement, of ZYNRELEF typical for setting fourth first separate January hospital of we the care in of a X, Exparel’s This cheaper end approval competitive strengths certainly pass-through specific This in than of pass-through takes ASC a forward local IDN years. In setting expect us. three-year by C-code even
economic is, reimbursement payment. of the separate outside an surgical XXXX. Our not of care. past. than commercial the I'll $XXX the accounts Today, purchase where are for benefit a on under customers surgical the may from settings of cases the ASCs. market I'll outpatient In ZYNRELEF surprising large on we've outstanding even without therapeutic million profitable has close and lives to these acquisition financial can reimbursement across focus using acquisition XXX bundle based customers cost ZYNRELEF. provides it's a of the hospital coverage compared the savings versions section benefits. incentive cost with over our also for benefits reimbursement, Based to team price per XXXB financial XX% Medicaid payment the than separate next access variety patient obtained be using a A the is on it's for XXXB a ASC of based cost Exparel. ZYNRELEF our IDNs that settings drug XX% is a the and more This priorities wide reimbursed times perspective, in reimbursement of of to for ZYNRELEF ZYNRELEF savings to now reimbursement XX% switch experience key conducting by covered Medicare to key some savings huge with component wholesale with WAC, outpatient in Switching We've care challenging paid and payers. our with shown setting. or lower evaluations. bundle strategy This in price slide these different in financial a on pricing XX% interchange rather done job offering benefits, patients Exparel. ZYNRELEF From and hospital and our And already
usage new leverage expanding growth. faster top to be existing indications is surgeon This accomplished the Our procedures. will for by priority new label an into
existing We are excellent to allow making with accounts also be in our newly indicated to formulary all approval ZYNRELEF restrictions progress us procedures. used remove of in surgical and
Based use of number outcomes increase ZYNRELEF experience practices. from their three actively routinely we surgeons accounts their surgeons within the patients, to expanded increasing initially excellent ZYNRELEF support by with priority with of account two usage usage second larger is ordering Our were using the only on colleagues. their ZYNRELEF. evaluated to or with utilizing Many
priority therapeutic interchange approvals targeted new formulary third of gain hospitals. and opportunities for the goal. to IDNs Increased Our key growth in this our access at is and pipeline is
continue of Xst making a hospital to reimbursement pass-through us bundle and a which year our the impact. outpatient indicators, April confidence payment setting gives positive a we'll The for will maximize significant is ZYNRELEF outside progress for XXXX already we've summary, the ZYNRELEF. ZYNRELEF. Finally, separate leading strong be already that status in In with made number growth of surgical
gears shift and the Now, for first review like oncology I'd quarter results our franchise. care to
our portfolio team our outstanding quarter. XX% generic growth This increase sales by did oncology units was net job in driven prior growing CINV of demand the clinic care, over of quarter, the setting first by a of During competition. the CINVANTI dominated a market an XX% by care
quarter guidance second XXXX Our range of the to CINV $XX $XX million. net is in million sales
As belief units demand and both, It's growth based during higher SUSTOL sold will quarter. factors. poised to key that XXXX, our bit for net CINVANTI are gross be in our two lower on on a revenue the
reimbursement reimbursement sales in we the to has see as of fosaprepitant $XX.XX price second improving tailwinds average First, XXXX. continue to generic quarter decreased
decreased Akynzeo’s proposition separate attractive over effective reimbursement segment IV $XXX has the will more addition, past outpatient CINVANTI the make ended, during year. hospital reimbursement which by the In ASP XXXX. January in Xst, in value much
SUSTOL value there's which less CINVANTI. and they So, both, can benefits offer,
experiencing, a Barry now bag million IV prior some increase XXXX CINV require to $XX As sales X% the doesn't net that potential over infusion the mentioned, bag. full-year we're an NK-X as in CINVANTI in representing XX% are range benefits shortage A year. $XX the providing of accounts guidance million, to IV only which tailwind
oncology that of over new patients remarks. call treatment, opportunities In majority a MEC addition, opportunity a as result will completes they create used as now products. since products be there's reenter HEC COVID the for in this patients of back the for of system to a backlog both turn believe I'll patients, my significant create we can both Barry. That the for prepared growth Barry? and
